LOSWIFT™Lactulose can acidify colonic contents by stimulating the growth of bifidobacteria, and its effect on secondary bile acid metabolism has been extensively studied. In a study involving middle-aged individuals (31-54 years) and elderly individuals (56-81 years), subjects were given 0.3 g/kg of LOSWIFT™Lactulose twice daily for 12 weeks. The results showed that after LOSWIFT™Lactulose administration, the concentration and excretion of secondary bile acids decreased. In addition, fecal weight increased and dry weight decreased; although intestinal transit time did not change, fecal pH values decreased after 6-12 weeks. In elderly individuals, deoxycholic acid levels in bile were higher, but cholic acid was lower. These studies indicate that LOSWIFT™Lactulose has a positive effect in reducing secondary bile acid levels and may have potential protective effects on colon health.

LOSWIFT™Lactulose has been widely used in the treatment of constipation, with a unique mechanism of action that is both safe and effective. Unlike traditional laxatives, LOSWIFT™Lactulose is not decomposed by the specific disaccharidase in the small intestine and can reach the colon unchanged, where it serves as an energy source for carbohydrate-splitting bacteria, predominantly lactobacillus acidophilus and L-bifidus. During this fermentation process, low molecular weight organic acids such as lactic acid and formic acid are produced. LOSWIFT™Lactulose can retain water in the intestine, increase fecal volume, stimulate intestinal peristalsis, and thereby promote defecation. Since the 1960s, LOSWIFT™Lactulose has been used to treat constipation in patients of all ages, including infants. As an osmotic laxative, it usually takes effect within 24-48 hours. Compared with traditional stimulant laxatives, LOSWIFT™Lactulose has a milder effect, does not cause intestinal spasms and electrolyte disorders, and is safe for long-term use, especially suitable for patients with chronic constipation and the elderly.

LOSWIFT™Lactulose plays an important role in reducing blood ammonia levels and is one of the key drugs in the treatment of hepatic encephalopathy. Hepatic encephalopathy is a central nervous system dysfunction caused by severe liver damage, which leads to ammonia metabolism disorders and elevated blood ammonia levels. LOSWIFT™Lactulose reduces bacterial production of ammonia in the intestines, draws ammonia from the blood to the colon, and then drains it through waste. It is hydrolysed by colonic bacteria and acts as promoting agent for their growth and increasing biomass formation. However, for the synthesis of bacterial protein, ammonia and nitrogen are used, but the production of ammonia is inhibited by acidifying the intestinal content. Studies showed that the concentration of ammonia in the blood in the control and LOSWIFT™Lactulose-treated groups after administration of meat is 12.65 ± 1.64 μg/mL and 8.45 ± 0.90 μg/mL, respectively. Independent of pH, LOSWIFT™Lactulose acts by increasing the incorporation of ammonia in the bacterial proteins. In addition, it has been shown in vitro that the LOSWIFT™Lactulose inhibits the synthesis and the activity of bacterial enzymes that generate ammonia. Studies have shown that patients with hepatic encephalopathy who take LOSWIFT™Lactulose have significant improvements in the number of abnormal neuropsychological tests, cognitive function, and quality of life.